IP Library Granted Patent US 10,875,883
Granted Patent B2
US 10,875,883 · App. 16/337,338 · Granted Dec 29, 2020

Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof

Inventors: Hong Liu (Shanghai, CN); Jiang Wang (Shanghai, CN); Shengbin Zhou (Shanghai, CN); Panfeng Peng (Shanghai, CN); Yong Nian (Shanghai, CN); Shuni Wang (Shanghai, CN); Shuangjie Shu (Shanghai, CN); Hao Shen (Shanghai, CN); Hualiang Jiang (Shanghai, CN); Kaixian Chen (Shanghai, CN)
Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
C07F15/045C07C227/34C07C229/34C07D207/16C07D401/04C07D409/12C07F15/04Y02P20/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,875,883
App. No.
16/337,338
Granted
Dec 29, 2020
Kind
B2
Abstract

Disclosed is a method for synthesizing a novel chiral ligand, a metal chelate, a variety of non-natural amino acids, Maraviroc and a key intermediate thereof. In the invention, (R)-2-methyl proline is selected and used as a starting raw material, (S)-β 3 -amino acid is obtained by asymmetric resolution induced by using a nickel chelate, and Maraviroc is synthesized by using (S)-3-amino-3-phenylpropionic acid as a key intermediate with a high yield and the ee value reaching 98.2% or more. The method of the present invention has widely available materials, mild synthetic process conditions, is easy to control, and produces a product of a high optical purity.

Claims (19)

1. A novel resolution method for an alpha amino acid, an alpha substituted beta amino acid and a beta substituted beta amino acid comprising the step of hydrolyzing a compound of formula VI to obtain the alpha amino acid, the alpha substituted beta amino acid and the beta substituted beta amino acid of formula VII,

wherein n is an integer from 1 to 4, m is an integer from 0 to 1;

R is selected from the group consisting of C1-C4 alkyl, C1-C4 haloalkyl and unsubstituted or substituted phenyl, wherein the substituted phenyl means that the phenyl has 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl;

R 1 is selected from the group consisting of H, C1-C4 alkyl, C1-C4 haloalkyl and unsubstituted or substituted phenyl, wherein the substituted phenyl means that the phenyl has 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl;

R 2 is selected from the group consisting of H, halogen, amino, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl;

R 3 is selected from the group consisting of H, C1-C4 alkyl, C1-C4 haloalkyl, unsubstituted or substituted phenyl and —(C1-C4 alkylene)-(unsubstituted or substituted phenyl); wherein the substituted phenyl means that the phenyl has 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, C1-C4 alkyl and C1-C4 haloalkyl;

R 4 is selected from the group consisting of H, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted C3-C6 heteroaryl and unsubstituted or substituted C3-C6 cycloalkyl, wherein the “substituted” means that there are 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, nitro, cyano, C1-C4 alkyl, C1-C4 alkoxy and C1-C4 haloalkyl;

R 5 is selected from the group consisting of H, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted C3-C6 heteroaryl and unsubstituted or substituted C3-C6 cycloalkyl, wherein the “substituted” means that there are 1-5 substituents, and each substituent is independently selected from the group consisting of amino, halogen, hydroxyl, nitro, cyano, C1-C4 alkyl, C1-C4 alkoxy and C1-C4 haloalkyl.

2. The resolution method of claim 1 , wherein the compound of VI is synthesized by the following step:

reacting a compound of formula IV with an unnatural amino acid of formula V under the action of a nickel salt to form the compound of formula VI,

wherein n, m, R, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 1 .

3. A Maraviroc intermediate having a structure of formula VI:

wherein n, m, R 1 , R 2 , R 3 , R 4 an R 5 areas defined in claim 1 .

4. The resolution method of claim 2 , wherein the compound of IV is synthesized by the following step:

(i) reacting (R)-2-substituted proline with di-tert-butyl dicarbonate to form (R)-1-(tert-butoxycarbonyl)-2-methylproline;

(ii) subjecting (R)-1-(tert-butoxycarbonyl)-2-substituted proline to a condensation reaction with a compound of formula I to obtain a compound of formula II;

(iii) removing tert-butoxycarbonyl from the compound of formula II to obtain a compound of formula III;

(iv) subjecting the compound of formula III to a reductive amination reaction with R 3 CHO or R 3 CH 2 Cl to obtain a compound of formula IV,

wherein n, R, R 1 , R 2 and R 3 are as defined in claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2019
From: LIU, HONG; WANG, JIANG; ZHOU, SHENGBIN; PENG, PANFENG; NIAN, YONG; WANG, SHUNI; SHU, SHUANGJIE; SHEN, HAO; JIANG, HUALIANG; CHEN, KAIXIAN
To: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Reel/Frame 048957/0020 →
Priority Claims (1)
CN 2016 1 0871043 · Sep 29, 2016 · national
Continuity (1)
Related Publication 20190233456A1 · Aug 1, 2019